Literature DB >> 21495173

Cardio-facio-cutaneous syndrome: does genotype predict phenotype?

Judith E Allanson1, Göran Annerén, Yoki Aoki, Christine M Armour, Marie-Louise Bondeson, Helene Cave, Karen W Gripp, Bronwyn Kerr, Anna-Maja Nystrom, Katia Sol-Church, Alain Verloes, Martin Zenker.   

Abstract

Cardio-facio-cutaneous (CFC) syndrome is a sporadic multiple congenital anomalies/mental retardation condition principally caused by mutations in BRAF, MEK1, and MEK2. Mutations in KRAS and SHOC2 lead to a phenotype with overlapping features. In approximately 10–30% of individuals with a clinical diagnosis of CFC, a mutation in one of these causative genes is not found. Cardinal features of CFC include congenital heart defects, a characteristic facial appearance, and ectodermal abnormalities. Additional features include failure to thrive with severe feeding problems, moderate to severe intellectual disability and short stature with relative macrocephaly. First described in 1986, more than 100 affected individuals are reported. Following the discovery of the causative genes, more information has emerged on the breadth of clinical features. Little, however, has been published on genotype–phenotype correlations. This clinical study of 186 children and young adults with mutation-proven CFC syndrome is the largest reported to date. BRAF mutations are documented in 140 individuals (approximately 75%), while 46 (approximately 25%) have a mutation in MEK 1 or MEK 2. The age range is 6 months to 32 years, the oldest individual being a female from the original report [Reynolds et al. (1986); Am J Med Genet 25:413–427]. While some clinical data on 136 are in the literature, 50 are not previously published. We provide new details of the breadth of phenotype and discuss the frequency of particular features in each genotypic group. Pulmonary stenosis is the only anomaly that demonstrates a statistically significant genotype–phenotype correlation, being more common in individuals with a BRAF mutation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21495173      PMCID: PMC3086095          DOI: 10.1002/ajmg.c.30295

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  27 in total

1.  Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome.

Authors:  H van Den Berg; R C Hennekam
Journal:  J Med Genet       Date:  1999-10       Impact factor: 6.318

2.  Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.

Authors:  Pablo Rodriguez-Viciana; Osamu Tetsu; William E Tidyman; Anne L Estep; Brenda A Conger; Molly Santa Cruz; Frank McCormick; Katherine A Rauen
Journal:  Science       Date:  2006-01-26       Impact factor: 47.728

3.  Non-hodgkin lymphoma in a patient with cardiofaciocutaneous syndrome.

Authors:  Akira Ohtake; Yoko Aoki; Yuka Saito; Tetsuya Niihori; Atsushi Shibuya; Shigeo Kure; Yoichi Matsubara
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

4.  Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.

Authors:  Martin Zenker; Katarina Lehmann; Anna Leana Schulz; Helmut Barth; Dagmar Hansmann; Rainer Koenig; Rudolf Korinthenberg; Martina Kreiss-Nachtsheim; Peter Meinecke; Susanne Morlot; Stefan Mundlos; Anne S Quante; Salmo Raskin; Dirk Schnabel; Lars-Erik Wehner; Christian P Kratz; Denise Horn; Kerstin Kutsche
Journal:  J Med Genet       Date:  2006-10-20       Impact factor: 6.318

5.  Germline gain-of-function mutations in SOS1 cause Noonan syndrome.

Authors:  Amy E Roberts; Toshiyuki Araki; Kenneth D Swanson; Kate T Montgomery; Taryn A Schiripo; Victoria A Joshi; Li Li; Yosuf Yassin; Alex M Tamburino; Benjamin G Neel; Raju S Kucherlapati
Journal:  Nat Genet       Date:  2006-12-03       Impact factor: 38.330

6.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

7.  New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome.

Authors:  J F Reynolds; G Neri; J P Herrmann; B Blumberg; J G Coldwell; P V Miles; J M Opitz
Journal:  Am J Med Genet       Date:  1986-11

8.  Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.

Authors:  Tetsuya Niihori; Yoko Aoki; Yoko Narumi; Giovanni Neri; Hélène Cavé; Alain Verloes; Nobuhiko Okamoto; Raoul C M Hennekam; Gabriele Gillessen-Kaesbach; Dagmar Wieczorek; Maria Ines Kavamura; Kenji Kurosawa; Hirofumi Ohashi; Louise Wilson; Delphine Heron; Dominique Bonneau; Giuseppina Corona; Tadashi Kaname; Kenji Naritomi; Clarisse Baumann; Naomichi Matsumoto; Kumi Kato; Shigeo Kure; Yoichi Matsubara
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

9.  Germline mutations in HRAS proto-oncogene cause Costello syndrome.

Authors:  Yoko Aoki; Tetsuya Niihori; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Yukichi Tanaka; Mirella Filocamo; Kumi Kato; Yoichi Suzuki; Shigeo Kure; Yoichi Matsubara
Journal:  Nat Genet       Date:  2005-09-18       Impact factor: 38.330

10.  Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.

Authors:  Marco Tartaglia; Len A Pennacchio; Chen Zhao; Kamlesh K Yadav; Valentina Fodale; Anna Sarkozy; Bhaswati Pandit; Kimihiko Oishi; Simone Martinelli; Wendy Schackwitz; Anna Ustaszewska; Joel Martin; James Bristow; Claudio Carta; Francesca Lepri; Cinzia Neri; Isabella Vasta; Kate Gibson; Cynthia J Curry; Juan Pedro López Siguero; Maria Cristina Digilio; Giuseppe Zampino; Bruno Dallapiccola; Dafna Bar-Sagi; Bruce D Gelb
Journal:  Nat Genet       Date:  2006-12-13       Impact factor: 38.330

View more
  27 in total

Review 1.  Genetic contribution to neurodevelopmental outcomes in congenital heart disease: are some patients predetermined to have developmental delay?

Authors:  Caitlin K Rollins; Jane W Newburger; Amy E Roberts
Journal:  Curr Opin Pediatr       Date:  2017-10       Impact factor: 2.856

2.  In vivo severity ranking of Ras pathway mutations associated with developmental disorders.

Authors:  Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

3.  LEOPARD Syndrome: Clinical Features and Gene Mutations.

Authors:  E Martínez-Quintana; F Rodríguez-González
Journal:  Mol Syndromol       Date:  2012-08-29

Review 4.  Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Mary Ella M Pierpont; Pilar L Magoulas; Saleh Adi; Maria Ines Kavamura; Giovanni Neri; Jacqueline Noonan; Elizabeth I Pierpont; Kent Reinker; Amy E Roberts; Suma Shankar; Joseph Sullivan; Melinda Wolford; Brenda Conger; Molly Santa Cruz; Katherine A Rauen
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

5.  Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation.

Authors:  Shahana Mitra; Baijayanti Ghosh; Nilanjan Gayen; Joydeep Roy; Atin K Mandal
Journal:  J Biol Chem       Date:  2016-10-04       Impact factor: 5.157

6.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

Review 7.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

8.  Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation.

Authors:  Robert M Harmon; Cory L Simpson; Jodi L Johnson; Jennifer L Koetsier; Adi D Dubash; Nicole A Najor; Ofer Sarig; Eli Sprecher; Kathleen J Green
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

9.  Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?

Authors:  M J M Nowaczyk; B A Thompson; S Zeesman; U Moog; P A Sanchez-Lara; P L Magoulas; R E Falk; J E Hoover-Fong; D A S Batista; S M Amudhavalli; S M White; G E Graham; K A Rauen
Journal:  Clin Genet       Date:  2013-04-02       Impact factor: 4.438

10.  Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.

Authors:  Alyson K Freeman; Daniel A Ritt; Deborah K Morrison
Journal:  Mol Cell       Date:  2013-01-24       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.